Md Reduanul Haque Kavey

Mr. Md Reduanul Haque Kavey

Pharmacy, Islamic University, Kushtia, Bangladesh
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2025 in Computational Biology and Chemistry
Verified
Journal Article
Closed access
SHShamim
Shamim
SASumon Ali
Sumon Ali
AHArju Hossain
Arju Hossain
AHAlfaz Hossain
Alfaz Hossain
Md Reduanul Haque KaveyMd Reduanul Haque Kavey
Md Reduanul Haque Kavey
MRMd Habibur Rahman
Md Habibur Rahman

1 October 2025 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
AHAlfaz Hossain
Alfaz Hossain
FFFahmida Mariam Fariha
Fahmida Mariam Fariha
AHArju Hossain
Arju Hossain
Md Reduanul Haque KaveyMd Reduanul Haque Kavey
Md Reduanul Haque Kavey
SHShamim
Shamim
HRHabibur Rahman
Habibur Rahman
Background: Triple-negative breast cancer (TNBC) is an aggressive subtype characterized by the absence of estrogen and progesterone receptors (ER, PR) and low or absent HER2 expression, limiting treatment options. Quercetin, a flavonoid with anti-cancer properties, has the potential to be a therapeutic intervention. Objectives: The study aimed to explore the potential of Quercetin derivatives as therapeutic agents for TNBC using several computational methods. Methods: The study utilized PASS prediction, molecular docking, ADMET prediction, QSAR models, MD simulations, binding free energy, and DFT calculations to evaluate the efficacy of quercetin derivatives. Results: ADMET analysis confirmed the solubility, non-carcinogenicity, and low toxicity of four quercetin derivatives: LM01, LM02, LM05, and LM10. These derivatives exhibited strong binding affinity against TNBC protein PPAR1, with binding energies of -10.6, -10.7, -11.4, and -10 kcal/mol, respectively. MD simulations confirmed their stability, with consistent RMSD values and favorable RMSF values. Post-simulation calculations and reduced HOMO-LUMO energy gaps further supported their potential as promising candidates. Conclusion: Our computational findings suggest that quercetin derivatives, particularly LM01, LM02, and LM10, exhibit strong stability and binding affinity, positioning them as promising candidates for TNBC treatment. Further experimental validation is required to confirm their therapeutic potential.

8 April 2026 in Biology
Verified
Journal Article
Open access
PDF file
JBJoy Baisnab
Joy Baisnab
MIMd. Saiful Islam
Md. Saiful Islam
Md Reduanul Haque KaveyMd Reduanul Haque Kavey
Md Reduanul Haque Kavey
SSS. M. Yasin Shourav
S. M. Yasin Shourav
RHRiaz Hosen
Riaz Hosen
Md. Rasul KarimMd. Rasul Karim
Md. Rasul Karim
Ixora chinensis Lam. has traditionally been used to treat conditions such as acne, high blood pressure, bleeding, tuberculosis, and rheumatism. This study aimed to investigate the methanolic extract of I. chinensis leaves to determine their bioactive compounds and evaluate their effects on both central and peripheral pain using in vivo and in silico approaches. The GC-MS analysis revealed 41 phytochemicals, including 14 phenolics, 4 esters, 12 terpenoids, 8 alkaloids, and 3 sulfur-containing compounds. In the glucose tolerance test, both the chloroform-soluble fraction (CF) and n-hexane fraction (NHF) exhibited p < 0.05 reductions in blood glucose levels at a dosage of 400 mg/kg with decreases of 51.94% and 46.63%, respectively, compared to the positive control (64.02%). The central analgesic evaluation showed significant (p < 0.001) enhancements in tail-flick latency for the fraction (184.94%) and CF (170.51%) following 90 min. In the pain relief assay, NHF showed inhibition (64.33%, p < 0.001) followed by an aqueous fraction (57.35%). These pharmacological findings were supported by in silico analysis. Concerning activity, 5-(dimethylamino)-1- acid phenyl ester (−8.9 kcal/mol) and 9,9-dimethyl-9H-fluoren-3-ol (−8.4 kcal/mol) displayed the strongest binding affinity to AMPK. Additionally, 2,3-diphenyl-2-cyclopropen-1-one exhibited favorable interactions with α-amylase (−8.0 kcal/mol) and α-glucosidase (−8.3 kcal/mol). Similarly, the central analgesic effect correlated with the strong μ-opioid receptor affinity of s-Triazine, 2-amino-4-(piperidinomethyl)-4-piperidino (−8.8 kcal/mol). N-Methyl-N-(4-toluenesulfonyl)-benzamide (−8.6 kcal/mol) and s-Triazine derivative (−8.9 kcal/mol) demonstrated notable COX-1 and COX-2 inhibition potential. Overall, the findings indicate I. chinensis leaves as a promising source of bioactive compounds with significant antihyperglycemic and analgesic properties.

17 October 2025 in In Silico Pharmacology
Verified
Journal Article
Closed access
PDF file
Md Reduanul Haque KaveyMd Reduanul Haque Kavey
Md Reduanul Haque Kavey
AHArju Hossain
Arju Hossain
SSShohanur Rahman Shohag
Shohanur Rahman Shohag
IAIrfan Aamer Ansari
Irfan Aamer Ansari
SASiddique Akber Ansari
Siddique Akber Ansari
MRMd Habibur Rahman
Md Habibur Rahman

1 February 2025 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
Md Abul BasharMd Abul Bashar
Md Abul Bashar
AHArju Hossain
Arju Hossain
Md Reduanul Haque KaveyMd Reduanul Haque Kavey
Md Reduanul Haque Kavey
RSRayhanuzzaman Shazib
Rayhanuzzaman Shazib
SIShofiqul Islam
Shofiqul Islam
HRHabibur Rahman
Habibur Rahman
Background: About 10-15% of all breast cancers comprise triple-negative breast cancer (TNBC), defined as cancer cells that lack ER, PR, and HER2 protein receptors. Due to the absence of these receptors, treating TNBC using conventional chemotherapy is challenging and, therefore, requires the discovery of novel chemotherapeutic agents derived from natural sources. Objective: The current work was intended to study the potential phytochemicals of Ajwa dates (Phoenix dactylifera L.) with the predicted potential targets (namely, Akt and PI3K) to determine possible TNBC inhibitors. Methods: We harnessed network pharmacology, molecular docking, drug-likeness studies, Molecular Dynamics (MD) simulation, and binding free energy (MM-GBSA) calculation to get phytochemicals with potential effects against TNBC. Firstly, molecular docking was performed on 125 phytochemicals against the Akt and PI3K proteins utilizing PyRx. Then, the phytochemicals with the highest binding affinity (≤ -8.1 kcal/mol) were examined for in silico drug-likeness and toxicity profiles. Finally, phytochemicals with optimal druglikeness and toxicity profiles were studied by Molecular Dynamics (MD) simulation and binding free energy (MM-GBSA) to identify compounds that can form stable complexes. Results: The results of the network pharmacology revealed that the Akt and PI3K proteins are potential targets of TNBC for the phytochemicals of Phoenix dactylifera L. used in this study. The outcomes of molecular docking displayed that among 125 phytochemicals, 42 of them (with a binding affinity ≤ -8.1 kcal/mol) have potentially inhibiting effects on both proteins PI3K and Akt expressed in TNBC. Then, the results of in silico drug-likeness identified seven phytochemicals with optimal pharmacokinetic profiles. Furthermore, toxicity studies showed that three phytochemicals (namely, Chrysoeriol, Daidzein, and Glycitein) did not cause any toxicities. Finally, the Molecular Dynamics (MD) simulation studies and binding free energy (MM-GBSA) verified that Daidzein stayed within the binding cavities of both proteins (Akt and PI3K) by establishing a stable protein-ligand complex during simulation. Conclusion: Taken together, the current work emphasizes the potential effects of Daidzein from Phoenix dactylifera L. against TNBC, and it can be further studied to establish it as a standard chemotherapy for TNBC.